Aspirin for Chest Pressure in Acute Coronary Syndrome
For a patient presenting with chest pressure suggestive of acute coronary syndrome, immediately administer a loading dose of 162-325 mg of non-enteric coated aspirin (chewed for faster absorption), followed by 75-100 mg daily maintenance dosing. 1, 2
Loading Dose Administration
- Give 162-325 mg orally as soon as possible upon presentation, regardless of whether the patient is already taking aspirin 1, 2
- Have the patient chew the aspirin (non-enteric coated) to achieve faster onset of antiplatelet action 2
- If oral administration is impossible, use rectal or intravenous routes (where available) 1
- Administer this loading dose immediately, irrespective of whether an invasive or noninvasive management strategy is planned 1
Maintenance Dosing
After the loading dose, transition to 75-100 mg daily of non-enteric coated aspirin 1, 2. This low-dose regimen:
- Exceeds the minimal effective dose needed for platelet thromboxane A₂ suppression 1
- Reduces major adverse cardiovascular events (MACE) and death 1, 2
- Causes significantly less gastrointestinal and minor bleeding compared to higher maintenance doses (300-325 mg daily) 2
The 2025 ACC/AHA/ACEP/NAEMSP/SCAI guidelines provide Class I, Level A evidence supporting this approach, making it the strongest possible recommendation based on the most recent and highest quality data 1, 2.
Critical Contraindications
Absolute contraindications to aspirin include:
- Documented aspirin hypersensitivity - though aspirin desensitization is preferred whenever possible to allow dual antiplatelet therapy 1
- Active severe bleeding 3
- Recent history of severe allergic reaction to aspirin (hives, facial swelling, asthma/wheezing, shock) 3
Relative contraindications and high-risk situations requiring caution:
- Age ≥60 years (increased stomach bleeding risk) 3
- History of stomach ulcers or bleeding problems 3
- Concurrent use of blood thinners (anticoagulants) or steroids 3
- Concurrent use of other NSAIDs 3
- Three or more alcoholic drinks daily 3
- Children/teenagers with viral illnesses (Reye's syndrome risk) 3
Important Clinical Pitfalls
Avoid NSAIDs for chest pain management - Non-aspirin NSAIDs are associated with increased MACE risk in ACS patients with no documented benefit 1, 2. Use nitroglycerin or opioids for pain relief instead.
Do not use enteric-coated aspirin for the loading dose - this delays absorption and antiplatelet effect 2. Non-enteric coated formulations are essential for both loading and maintenance phases.
If aspirin hypersensitivity exists, a P2Y12 inhibitor should still be administered with a loading dose as early as possible 1. Consider aspirin desensitization protocols to enable dual antiplatelet therapy 1.
Dual Antiplatelet Therapy
Aspirin alone is insufficient. All ACS patients require addition of a P2Y12 inhibitor (clopidogrel, prasugrel, or ticagrelor) on top of aspirin 1, 2. This dual antiplatelet therapy (DAPT) significantly reduces recurrent MACE, though it increases bleeding risk 2.
Special consideration for ticagrelor: When using ticagrelor, aspirin maintenance doses must be ≤100 mg daily 1.